Achillion Pharmaceuticals, which is Developing novel treatments for infectious diseases, including HIV and Hepatitis C, priced its initial public offering of 4.5 million shares at $11.50, below its proposed $14 to $16 price range, on Wednesday night. Cowen & Company and CIBC World Markets were the lead underwriters on the deal. The stock is expected to begin trading on the NASDAQ under the ticker ACHN on Thursday.
